On July 14, WuXi Biologics fell 3.27% in regular trading, trading at HK$37.0 per share, with turnover of HK$245 million.
Within the Life Sciences Tools & Services sector where WuXi Biologics belongs, the overall sector performance skewed weak. Among individual stocks, PHARMARON up 1.98%, WUXI APPTEC up 1.25%, INSILICO down 2.49%, GENSCRIPT BIO down 2.65%, XTALPI down 6.48%.
WuXi Biologics is a global leading contract research, development, and manufacturing organization (CRDMO) for biologics, providing end-to-end solutions and services from drug discovery to commercial manufacturing for pharmaceutical companies worldwide, covering biologics, antibody-drug conjugates, and other therapeutic areas.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments